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nystatin oral suspension is a safe first-
line therapy; fluconazole is more effective 
(strength of recommendation [sor]: B, 1 
small randomized controlled trial [rCT]) 
but has not been approved by the Food 
and Drug Administration (FDA) for use in 
immunocompetent infants. Miconazole 
oral gel is also more effective than nystatin 
suspension, but is not commercially 
available in the united states (sor: B, 
one small rCT). Gentian violet may be 
effective, but it stains skin and clothes and 
is associated with mucosal ulceration (sor: 
B, 1 small retrospective cohort study).
clinical commentary
fluconazole isn’t worth the higher cost
I reassure parents that oral thrush in 
infants is rarely a sign of serious illness 
and recommend nystatin suspension  
0.5 cc qid––a smaller dose than reported 
in this review. larger doses are more often 
spit out or swallowed, and at the smaller 
dose, a 60-ml bottle suppresses the 
yeast adequately for 2 weeks. My goal 
is to suppress yeast overgrowth until the 
infant’s immune system and bacterial flora 
mature. This review doesn’t convince me 
that fluconazole, which costs more than 
nystatin, is worth the added expense. 
Gentian violet is very messy, and I rarely 
recommend it. For refractory thrush in 
breastfed infants, I recommend that the 
mother apply a topical antifungal to the 
nipple area.
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Fluconazole is 
more effective 
than nystatin oral 
suspension, but 
costs more and is 
an off-label use for 
healthy infants z	Evidence	summary
Few studies have compared treatment 
options for oropharyngeal candidiasis in 
immunocompetent infants. In a survey of 
312 health care providers, approximately 
75% of the respondents reported treat-
ing thrush with oral nystatin, citing fewer 
side effects and lower cost.1 However, ny-
statin has proved less effective than either 
miconazole gel or oral fluconazole.
Nystatin	is	safe	and	available,		
but	other	options	work	better
miconazole vs nystatin. An unblinded 
RCT assigned 83 immunocompetent 
infants with culture-positive oral thrush 
to receive either 25 mg miconazole oral 
gel (not commercially available in the 
United States) or nystatin suspension (1 
mL of 100,000 IU/mL) qid after meals. 
The clinical cure rate, defined as absence 
of plaques by day 12, was significantly 
higher in the miconazole group (99% for 
miconazole, 54% for nystatin; P<.0001, 
number needed to treat [NNT]=2). The 
eradication rate, confirmed by cultures 
collected in a blinded manner on the 
day of clinical cure, was also higher in 
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Refractory thrush 
in breastfed  
infants may  
respond  
to a topical  
antifungal applied 
to the mother’s 
nipples
the miconazole group (55.7% for mi-
conazole, 15.2% for nystatin; P<.0001, 
NNT=3). In successfully treated pa-
tients, infection recurred with similar 
frequency in both treatment groups 
within 4 weeks (miconazole, 12.4%; 
nystatin, 13.0%). Side effects—mostly 
vomiting and, infrequently, diarrhea—
were rare in both groups (miconazole, 
4.5%; nystatin 3.5%).2 
An earlier, unblinded RCT of 95 
infants compared miconazole gel to 2 
nystatin oral gels (gel A: 250,000 IU/g 
with 250,000 IU administered as single 
dose; gel B: 100,000 IU/g with 50,000 
IU administered as single dose). Each 
medication was given qid over the 
course of 8 to 14 days. The study con-
firmed higher clinical cure rates with 
miconazole gel (85.1% for miconazole 
vs 42.8% for nystatin gel A [P<.0007, 
NNT=2] and 48.5% for nystatin gel B 
[P<.004, NNT=3]).3
fluconazole vs nystatin. In the only 
prospective RCT (unblinded) to com-
pare oral suspensions of fluconazole 
and nystatin, 34 infants were random-
ized to receive either nystatin (1 mL 
of 100,000 IU/mL) qid for 10 days 
or fluconazole (3 mg/kg) once a day 
for 7 days. Mothers of breastfed in-
fants applied nystatin cream to their 
nipples twice a day for the duration 
of the infant’s treatment. The clinical 
cure rate—defined as absence of oral 
plaques at the end of therapy (day 10 
for the nystatin group, day 7 for the 
fluconazole group)—was significantly 
higher in the group treated with fluco-
nazole (100% for fluconazole, 32% for 
nystatin; P<.0001, NNT=2). The eradi-
cation rate was also higher with fluco-
nazole (73.3% for fluconazole, 5.6% 
for nystatin; P<.0001, NNT=2). The 
patients treated with fluconazole ex-
perienced no side effects.4 Fluconazole 
has been shown to be effective, safe, 
and easy to use to treat thrush in im-
munocompromised children,5 but has 
not been approved by the FDA for use 
in healthy infants. 
Gentian	violet	is	effective,		
but	messy	and	irritating	
A retrospective cohort study that re-
viewed 69 cases of oral thrush showed 
that gentian violet achieved a 75% cure 
rate in an average of 11 days (compared 
to 55% in 10 days for nystatin). Both 
treatments shortened the duration of 
illness compared with the average of 
34 days for untreated children.6 How-
ever, gentian violet can stain skin and 
clothes, and case studies have shown an 
association with ulceration of the buccal 
mucosa.7 
Recommendations
A thorough literature search through 
the Cochrane Database Systematic Re-
views, Agency for Healthcare Research 
and Quality, National Guideline Clear-
inghouse, and Medline did not yield any 
guidelines or consensus statements from 
other organizations or specialty groups 
on treating oropharyngeal candidiasis in 
infants. Neither the American Academy 
of Pediatrics nor the Infectious Diseases 
Society of America has issued applicable 
practice guidelines. n
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